Kodiak Sciences Inc.

KOD

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$38.33

−$1.51 · -3.79%

Aug 21, 4:00 PM ET

Pre-market

$38.46

+$0.13 · +0.34%

Aug 24, 8:44 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

44/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Gaining

Sentiment

Bullish

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Victor Perlroth
Listed since: Oct 4, 2018
Employees: 141

Market position

Day range

Current $38.33

$38.15$40.50

52-week range

Current $38.33

$8.29$47.84

Open: $40.16
Previous close: $39.84
Volume: 509.12K; 0.74× average
Average volume: 684.37K; Average daily volume
Market cap: 2.4B USD
Beta: 2.21; Market reference 1
50-day average: $39.7646; -3.61% below average
200-day average: $32.1881; +19.08% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -9.15×
P/B (TTM): 39.29×
P/S (TTM): 0×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%

Financial health

Debt / equity: 1.57×
Altman Z-score: -4.53
Piotroski F-score: 1 of 9

Financial statements

Income trends

Operating income

−234.39M USD-25.44%

Net income

−229.97M USD-30.51%

Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	—	26.71M USD	25.95M USD	11M USD	8.71M USD
Gross profit	—	−26.71M USD	−25.95M USD	−11M USD	−8.71M USD
Research and development	182.37M USD	126.1M USD	206.3M USD	267.59M USD	217.34M USD
Selling, general, and administrative	52.02M USD	34.05M USD	71.02M USD	62.79M USD	41M USD
Operating expenses	234.39M USD	160.14M USD	251.37M USD	330.38M USD	258.34M USD
Interest income	4.52M USD	11.15M USD	16.73M USD	7.07M USD	298K USD
Interest expense	—	—	13K USD	18K USD	22K USD
Depreciation and amortization	26.32M USD	26.71M USD	25.95M USD	11M USD	8.71M USD
Operating income	−234.39M USD	−186.85M USD	−277.32M USD	−341.38M USD	−267.05M USD
Net income	−229.97M USD	−176.21M USD	−260.49M USD	−333.82M USD	−266.99M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

18 ratings

Strong buy00%

Buy1372%

Hold422%

Sell16%

Strong sell00%

KOD news

zacks.comAug 14, 2026

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

Read source

prnewswire.comAug 13, 2026

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results

PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026.

Read source

zacks.comAug 11, 2026

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.

Read source

prnewswire.comAug 10, 2026

Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a…

Read source

prnewswire.comAug 6, 2026

Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of enrollment in the second pivotal cohort evaluating 600 subjects across…

Read source

defenseworld.netJul 19, 2026

Kodiak Sciences (NASDAQ:KOD) Shares Up 6.6% – What’s Next?

Shares of Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shot up 6.6% on Friday. The company traded as high as $43.94 and last traded at $43.9590. Approximately 68,404 shares changed hands during trading, a decline…

Read source